Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer

Prapti A. Patel

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


5-Fluorouracil (5-FU) is the most widely used agent for the management of colorectal cancer. Capecitabine is metabolized by three enzymatic actions, the last of which is mediated by thymidine phosphorylase, to produce 5-FU. Given the oral bioavailability of capecitabine as well as in-vitro and in-vivo findings showing higher expression of thymidine phosphorylase in tumor cells and xenografts compared with normal tissue, capecitabine is an evolving candidate in the management of colorectal cancer with antimetabolite-based therapy. An ideal radiosensitizing agent must balance oncological outcomes with adverse effects and feasibility of administration. This discussion addresses the evolving role of 5-FU in the management of rectal cancer in the neoadjuvant setting in combination with ionizing radiation.

Original languageEnglish (US)
Pages (from-to)311-316
Number of pages6
JournalAnti-Cancer Drugs
Issue number4
StatePublished - Apr 1 2011


  • 5-FU
  • pathologically complete response
  • radiosensitizing agents
  • rectal cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research


Dive into the research topics of 'Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer'. Together they form a unique fingerprint.

Cite this